Claim being checked · Version 1 · Reviewed
“Bremelanotide is FDA-approved for a specific form of HSDD.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Supported with scope. The reviewed evidence supports this exact statement only in the situation described below.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for Bremelanotide.
01 · Answer
Supported with scope
Vyleesi is approved for acquired, generalized HSDD in certain premenopausal women after specified exclusions.
- What kind of evidence this is
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- What this answer covers
- The population and limitations in the current Vyleesi label. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Approval and status. Whether a specific product has an approval or another official status.
02 · Sources
Read the sources behind this answer
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.